Effects of tumor-induced osteomalacia on the bone mineralization process

Calcified Tissue International

Volumn 84, Issue 4, 2009, Pages 313-323

  Nawrot Wawrzyniak, K ^a,b   Varga, F ^a,b   Nader, A ^a,b,c   Roschger, P ^a,b   Sieghart, S ^d   Zwettler, E ^a,b   Roetzer, K M ^a,b,e   Lang, S ^f   Weinkamer, R ^g   Klaushofer, K ^a,b   Fratzl Zelman, N ^h  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b HANUSCH HOSPITAL   (Austria)

^c Hanusch Hospital of WGKK   (Austria)

^d Kaiserin Elisabeth Hospital   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES   (Germany)

^h AUVA Soziale Unfallversicherung   (Austria)

Author keywords

Bone histomorphometry; Bone mineralization density distribution; Fibroblast growth factor 23; In situ hybridization; Tumor induced osteomalacia

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MATRIX; BONE MINERALIZATION; BONE TURNOVER; CALCIUM BONE LEVEL; CASE REPORT; CELL COUNT; CELL HETEROGENEITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HISTOPATHOLOGY; HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; ILIAC CREST; IN SITU HYBRIDIZATION; MALE; MORPHOMETRICS; ONCOGENIC OSTEOMALACIA; ORTHOPEDIC SURGERY; OSTEOBLAST; OSTEOCLAST; PARATHYROID HYPERPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCAPULA; TRABECULAR BONE; TUMOR CELL; TUMOR LOCALIZATION;

BONE NEOPLASMS; CALCIFICATION, PHYSIOLOGIC; CALCITRIOL; FIBROBLAST GROWTH FACTORS; HEMANGIOPERICYTOMA; HUMANS; HYPERPARATHYROIDISM; MALE; MESENCHYMOMA; MIDDLE AGED; OSTEOMALACIA; PARATHYROID NEOPLASMS; PARATHYROIDECTOMY; SCAPULA;

EID: 63949084274     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-009-9216-z     Document Type: Article

References (57)

1. T Shimada S Mizutani T Muto T Yoneya R Hino S Takeda Y Takeuchi T Fujita S Fukumoto T Yamashita 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia Proc Natl Acad Sci USA 98 6500 6505
2. T Shimada H Hasegawa Y Yamazaki T Muto R Hino Y Takeuchi T Fujita K Nakahara S Fukumoto T Yamashita 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis J Bone Miner Res 19 429 435
3. EA Ryan E Reiss 1984 Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases Am J Med 77 501 512
4. SM Jan de Beur 2005 Tumor-induced osteomalacia JAMA 294 1260 1267
5. KE White TE Larsson MJ Econs 2006 The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23 Endocr Rev 27 221 241
6. S Liu LD Quarles 2007 How fibroblast growth factor 23 works J Am Soc Nephrol 18 1637 1647
7. S Fukumoto 2008 Physiological regulation and disorders of phosphate metabolism-pivotal role of fibroblast growth factor 23 Intern Med 47 337 343
8. MK Drezner 2001 Tumor-induced osteomalacia Rev Endocr Metab Disord 2 175 186
9. J Seufert K Ebert J Muller J Eulert C Hendrich E Werner N Schuuze G Schulz W Kenn H Richtmann KD Palitzsch F Jakob 2001 Octreotide therapy for tumor-induced osteomalacia N Engl J Med 345 1883 1888
10. Y Yamazaki R Okazaki M Shibata Y Hasegawa K Satoh T Tajima Y Takeuchi T Fujita K Nakahara T Yamashita S Fukumoto 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia J Clin Endocrinol Metab 87 4957 4960
11. T Nasu S Kurisu S Matsuno K Tatsumi T Kakimoto M Kobayashi Y Nakano H Wakasaki H Furuta M Nishi H Sasaki H Suzuki N Ito S Fukumoto K Nanjo 2008 Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23 Intern Med 47 957 961
12. FM Hannan NA Athanasou J Teh CL Gibbons B Shine RV Thakker 2008 Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23,1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1 Eur J Endocrinol 158 265 271
13. X Bai D Miao J Li D Goltzman AC Karaplis 2004 Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders Endocrinology 145 5269 5279
14. T Larsson R Marsell E Schipani C Ohlsson O Ljunggren HS Tenenhouse H Juppner KB Jonsson 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis Endocrinology 145 3087 3094
15. T Shimada I Urakawa Y Yamazaki H Hasegawa R Hino T Yoneya Y Takeuchi T Fujita S Fukumoto T Yamashita 2004 FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa Biochem Biophys Res Commun 314 409 414
16. T Shimada M Kakitani Y Yamazaki H Hasegawa Y Takeuchi T Fujita S Fukumoto K Tomizuka T Yamashita 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism J Clin Invest 113 561 568
17. D Sitara MS Razzaque M Hesse S Yoganathan T Taguchi RG Erben H Juppner B Lanske 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice Matrix Biol 23 421 432
18. S Liu J Zhou W Tang X Jiang DW Rowe LD Quarles 2006 Pathogenic role of Fgf23 in Hyp mice Am J Physiol Endocrinol Metab 291 E38 E49
19. D Sitara MS Razzaque R St-Arnaud W Huang T Taguchi RG Erben B Lanske 2006 Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals Am J Pathol 169 2161 2170
20. JR Stubbs S Liu W Tang J Zhou Y Wang X Yao LD Quarles 2007 Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice J Am Soc Nephrol 18 2116 2124
21. M Murshed D Harmey JL Millan MD McKee G Karsenty 2005 Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone Genes Dev 19 1093 1104
22. JL Geller A Khosravi MH Kelly M Riminucci JS Adams MT Collins 2007 Cinacalcet in the management of tumor-induced osteomalacia J Bone Miner Res 22 931 937
23. T Hayashibara T Hiraga A Sugita L Wang K Hata T Ooshima T Yoneda 2007 Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions J Bone Miner Res 22 1743 1751
24. H Wang Y Yoshiko R Yamamoto T Minamizaki K Kozai K Tanne JE Aubin N Maeda 2008 Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro J Bone Miner Res 23 939 948
25. D Sitara S Kim MS Razzaque C Bergwitz T Taguchi C Schuler RG Erben B Lanske 2008 Genetic evidence of serum phosphate-independent functions of FGF-23 on bone PLoS Genet 4 e1000154
26. AM Parfitt 2003 Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry Curr Opin Nephrol Hypertens 12 387 403
27. D Ruffoni P Fratzl P Roschger K Klaushofer R Weinkamer 2007 The bone mineralization density distribution as a fingerprint of the mineralization process Bone 40 1308 1319
28. D Ruffoni P Fratzl P Roschger R Phipps K Klaushofer R Weinkamer 2008 The effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study J Bone Miner Res 23 1905 1914
29. P Roschger HS Gupta A Berzlanovich G Ittner DW Dempster P Fratzl F Cosman M Parisien R Lindsay JW Nieves K Klaushofer 2003 Constant mineralization density distribution in cancellous human bone Bone 32 316 323
30. P Roschger EP Paschalis P Fratzl K Klaushofer 2008 Bone mineralization density distribution in health and disease Bone 42 456 466
31. AM Parfitt MK Drezner FH Glorieux JA Kanis H Malluche PJ Meunier SM Ott RR Recker 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee J Bone Miner Res 2 595 610
32. P Roschger P Fratzl J Eschberger K Klaushofer 1998 Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies Bone 23 319 326
33. KM Roetzer F Varga E Zwettler K Nawrot-Wawrzyniak J Haller E Forster K Klaushofer 2007 Novel PHEX mutation associated with hypophosphatemic rickets Nephron Physiol 106 8 12
34. KE White KB Jonsson G Carn G Hampson TD Spector M Mannstadt B Lorenz-Depiereux A Miyauchi IM Yang O Ljunggren T Meitinger TM Strom H Juppner MJ Econs 2001 The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting J Clin Endocrinol Metab 86 497 500
35. B Bielesz K Klaushofer R Oberbauer 2004 Renal phosphate loss in hereditary and acquired disorders of bone mineralization Bone 35 1229 1239
36. Jan de Beur SM (2006) Tumor-induced osteomalacia. In: Favus M (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society of Bone and Mineral Research, Washington, DC, pp 345-351
37. N Ito S Fukumoto Y Takeuchi T Yasuda Y Hasegawa F Takemoto T Tajima K Dobashi Y Yamazaki T Yamashita T Fujita 2005 Comparison of two assays for fibroblast growth factor (FGF)-23 J Bone Miner Metab 23 435 440
38. A Khosravi CM Cutler MH Kelly R Chang RE Royal RM Sherry FM Wodajo NS Fedarko MT Collins 2007 Determination of the elimination half-life of fibroblast growth factor-23 J Clin Endocrinol Metab 92 2374 2377
39. Y Takeuchi H Suzuki S Ogura R Imai Y Yamazaki T Yamashita Y Miyamoto H Okazaki K Nakamura K Nakahara S Fukumoto T Fujita 2004 Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia J Clin Endocrinol Metab 89 3979 3982
40. EA Imel SL Hui MJ Econs 2007 FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets J Bone Miner Res 22 520 526
41. TJ Weber S Liu OS Indridason LD Quarles 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis J Bone Miner Res 18 1227 1234
42. EA Imel M Peacock P Pitukcheewanont HJ Heller LM Ward D Shulman M Kassem P Rackoff M Zimering A Dalkin E Drobny G Colussi JL Shaker EH Hoogendoorn SL Hui MJ Econs 2006 Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia J Clin Endocrinol Metab 91 2055 2061
43. R Marsell E Grundberg T Krajisnik H Mallmin M Karlsson D Mellstrom E Orwoll C Ohlsson KB Jonsson O Ljunggren TE Larsson 2008 Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men Eur J Endocrinol 158 125 129
44. T Larsson R Zahradnik J Lavigne O Ljunggren H Juppner KB Jonsson 2003 Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia Eur J Endocrinol 148 269 276
45. AL Folpe JC Fanburg-Smith SD Billings M Bisceglia F Bertoni JY Cho MJ Econs CY Inwards SM Jan de Beur T Mentzel E Montgomery M Michal M Miettinen SE Mills JD Reith JX O'Connell AE Rosenberg BP Rubin DE Sweet TN Vinh LE Wold BM Wehrli KE White RJ Zaino SW Weiss 2004 Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature Am J Surg Pathol 28 1 30
46. M Riminucci MT Collins NS Fedarko N Cherman A Corsi KE White S Waguespack A Gupta T Hannon MJ Econs P Bianco P Gehron Robey 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting J Clin Invest 112 683 692
47. K Kobayashi Y Imanishi H Koshiyama A Miyauchi K Wakasa T Kawata H Goto H Ohashi HM Koyano R Mochizuki T Miki M Inaba Y Nishizawa 2006 Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia Life Sci 78 2295 2301
48. K Kobayashi Y Imanishi A Miyauchi N Onoda T Kawata H Tahara H Goto T Miki E Ishimura T Sugimoto T Ishikawa M Inaba Y Nishizawa 2006 Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism Eur J Endocrinol 154 93 99
49. B Krempien E Ritz W Tschope 1980 The effect of 1,25 (OH)2D3 on bone mineralization: ultrastructural studies in patients with renal osteodystrophy Contrib Nephrol 18 122 134
50. M Parisien SJ Silverberg E Shane L de la Cruz R Lindsay JP Bilezikian DW Dempster 1990 The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure J Clin Endocrinol Metab 70 930 938
51. K Hollberg R Marsell M Norgard T Larsson KB Jonsson G Andersson 2008 Osteoclast polarization is not required for degradation of bone matrix in rachitic FGF23 transgenic mice Bone 42 1111 1121
52. ZS Xiao M Crenshaw R Guo T Nesbitt MK Drezner LD Quarles 1998 Intrinsic mineralization defect in Hyp mouse osteoblasts Am J Physiol 275 E700 E708
53. BM Misof P Roschger F Cosman ES Kurland W Tesch P Messmer DW Dempster J Nieves E Shane P Fratzl K Klaushofer J Bilezikian R Lindsay 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment J Clin Endocrinol Metab 88 1150 1156
54. P Roschger DW Dempster H Zhou EP Paschalis SJ Silverberg E Shane JP Bilezikian K Klaushofer 2007 New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging J Bone Miner Res 22 717 723
55. P Roschger P Fratzl K Klaushofer G Rodan 1997 Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs Bone 20 393 397
56. R Zoehrer P Roschger EP Paschalis JG Hofstaetter E Durchschlag P Fratzl R Phipps K Klaushofer 2006 Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women J Bone Miner Res 21 1106 1112
57. Freemont A (1995) Bone histomorphometry. In: Tovey F, Stamp T (eds) The measurement of metabolic bone disease. Parthenon, New York, pp 77-90